Apellis Pharmaceuticals, Inc. (BIT:1APLS)
Italy flag Italy · Delayed Price · Currency is EUR
18.71
-1.14 (-5.72%)
At close: Feb 11, 2026

Revenue

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021FY 2020
Period Ending
Sep '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
EMPAVELI Revenue
90.67M98.09M91.03M
EMPAVELI Revenue Growth
-7.56%7.75%39.85%
SYFOVRE Revenue
599.54M611.86M275.25M
SYFOVRE Revenue Growth
-2.01%122.30%-
Total Product Revenue
690.21M709.95M366.28M
Total Product Revenue Growth
-2.78%93.83%462.71%
Licensing and Other Revenue
326.18M71.41M30.31M
Licensing and Other Revenue Growth
356.76%135.61%193.42%
Revenue (Total)
1.02B781.37M396.59M
Revenue (Total) Growth
30.08%97.02%425.83%
Updated Sep 30, 2025. Data Source: Fiscal.ai.